Erythrocyte alloimmunization in polytransfused patients with onco-hematological diseases: A literature review
DOI:
https://doi.org/10.33448/rsd-v10i7.16575Keywords:
Alloimmunization; Irregular antibody; Erythocyte phenotyping; Onco-hematological diseases; Multi-transfused patients.Abstract
The purpose of this literature review was to evaluate which onco-hematologic diseases are most frequent in alloimmunized polytransfused patients, to determine which are the most common erythrocyte antigens and anti-erythrocyte alloantibodies detected in the study population profile, and to identify appropriate measures to be taken to minimize alloimmunization rates in this transfusion-dependent population. Well-defined eligibility criteria were used, and the search was conducted in the electronic bibliographic data base Medical Literature Analysis and Retrieval System Online (MEDLINE). Based on the criteria used, 10 articles were included in this review. It was found that the most prevalent onco-hematologic disease in the population studied was Myelodysplastic Syndrome and the most frequently detected alloantibodies were those associated with the Rh, Kell, MNS and Kidd systems. All the papers pointed to extensive erythrocyte phenotyping to minimize alloimmunization rates among patients with hematological neoplasms, as well as to reduce the risks of occurrence of transfusion hemolytic reactions. Therefore, performing phenotyping and genotyping to identify systems other than ABO/Rh, especially for chronically transfused patients who present with Myelodysplastic Syndrome, can minimize the risk of alloimmunization and its consequences with positive reflections on the safety and efficacy of transfusion therapy.
References
Abo el Fetouh, R. M., Abd Elmoniem, G. M., Allam, R. M., Sobeih, M. E., Kamel M. M., & Radwan, S. M. (2020). Frequency and specificity of Red blood cell alloantibodies in multitransfused Egyptian patients with hematological and non hematological malignancies. Transfusion and Apheresis Science, 59(6), 1-5.
Adati, M. C., Gemal, A. L., & Guedes, H. C. B. (2009). Resultados do controle de qualidade de produtos hemoderivados: análise sanitária. Rev Bras Hematol Hemoter, 31(4), 235-40.
Alves, V. M., Martins, P. R. J., Soares, S., Araujo, G., Schmidt, L. C., & Costa, S. S. M. (2012). Pesquisa de aloimunização após transfusão de concentrados de hemácias em um estudo prospectivo. Rev Bras Hematol Hemoter, 34(3), 206-11.
Araujo, W.C. O. (2020). Recuperação da informação em saúde: construção, modelos e estratégias. Conv Ciênc Inform, 3(2), 100-34.
Baia, F., Correia, F., Alves, B., Martinez, F., Koch, C., & Carneiro, A. (2016). Phenotyping Rh/Kell and risk of alloimmunization in haematological patients. Transfus Med, 26(1), 34-8.
Caamaño, J., Musante, E., Contreras, M., Ulloa, H., Reyes, C., & Inaipil, V. (2015). Frequency and specificity of red blood cell alloimmunization in chile an transfused patients. Transfus Med Hemother, 42(1), 4-7.
Celli, R., Schulz, W., Hendrickson, J. E., & Torney, C. A. (2017). A novel network analysis tool to identify relationships between disease states and risks for red blood cell alloimmunization. Vox Sang, 112(5), 469-72.
Chao, Y. H., Wu, K. H., Lu, J. J., Shih, M. C., Peng, C. T., & Chang, C. W. (2013). Red blood cell alloimmunization among Chinese patients with β-thalassaemia major in Taiwan. BloodTransfus, 11(1), 71-4.
Chung, S. S., & Park, C. Y. (2017). Aging, hematopoiesis, and the myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program, 2017(1), 73-8.
Daniels, G., & Reid, M. E. (2010). Blood groups: the past 50 years. Transfusion, 50(2), 281-9.
Delaney, M. D., Wendel, S., Bercovitz, R. S., Cid, J., Cohn, C., & Dunbar, N. M. D. (2016). Transfusion reactions: prevention, diagnosis, and treatment. The Lancet, 388(10061), 1-12.
Evers, D., Zwaginga, J. J., Tijmensen, J., Middelburg, R. A., Haas, M., & Vooght, K. M. K. (2017). Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization. Haematologica, 102(1), 52-9.
Frazier, S. K., Higgins, J., Bugajski, A., Jones, A. R., & Brown, M. R. (2017). Adverse reactions to transfusion of blood products and best practices for prevention. Crit Care Nurs Clin North Am, 29(3), 271-90.
Federici, A. B., Vanelli, C., & Arrigoni, L. (2012).Transfusion issues in cancer patients. Thrombosis Research, 129(1), 60-5.
García-Roa, M.,Vicente-Ayuso, M. D. C., Bobes, A. M., Pedraza, A. C., Gonzalez-Fernandez, A., & Martin, M. P. (2017). Red blood cell storage time and transfusion: current practice, concerns and future perspectives. Bloodtransfus, 15(3), 222-31.
Guelsin, G. A. S., Rodrigues, C., Visentainer, J. E. L., Campos, P. M., Traina, F., & Gilli, S. C. O. (2015). Molecular matching for Rh and K reduces red blood cell alloimmunization in patients with myelodisplastic syndrome. Blood Transfus,13(1), 53-8.
Hamerschlack, N. (2008). Leucemia: fatores prognósticos e genética. J Pediatr, 84(4), 52-7.
Handa, A.,Kukar, N., Maharishi, R. N.,Syal, N., & Arora, H. (2020). Analysis of red cell alloimmunization in multi transfused patients at a Tertiary care teaching hospital. J Family Med Prim Care, 9(6), 2907-11.
Hendrickson, J. E., & Tormey, C. A. (2016). Understanding red blood cell alloimmunization triggers. Hematology Am Soc Hematol Educ Program,2016(1), 446-51.
Ido, A. A. S., & Oliveira, M. C. (2020). Main Erythrocyte Antigens Involved in the Alloimmunization Process. Open Science Journal, 5(2), 2-10.
Kangiwa, U., Ibegbulam, O., Ocheni, S., & Madu, A., Mohammed, N. (2015). Pattern and prevalence of alloimmunization in multiply transfused patients with sickle cell disease in Nigeria. Biomark Res, 3(26).
Kim, H. Y., Cho, E. J., Chun, S., Kim, K. H., & Cho, D. (2019). Red Blood Cell Alloimmunization in Korean Patients With Myelodysplastic Syndrome and Liver Cirrhosis. Ann labmed, 39(2), 218-22.
Lamego, R.M., Clementino, N. C. D., Costa, A. L. B., Oliveira, M. J., & Bittencourt, H. (2010). Transplante alogênico de células-tronco hematopoéticas em leucemias agudas: a experiência de dez anos do Hospital das Clínicas da UFMG. Rev Bras Hematol Hemoter,32(2), 108-15.
Leisch, M., Weiss, L., Lindlbauer, N., Jungbauer, C., Egle, A., & Rohde, E. (2017). Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine: A retrospective single center experience. Leuk Res,59, 12-19.
Mangwana, S.,Kacker, A., & Simon, N. (2019). Red cell alloimmunization in multi-transfused, oncology patients: Risks and management. Glob J Transfus Med, 4(1), 74-8.
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D.G. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine, 6(7), 1-6.
Molina-Aguilar, R., Gómez-Ruiz, S., Vela-Ojeda, J.,Montiel-Cervantes, L.A., & Reyes-Maldonado, E. (2020).Pathophysiology of Alloimmunization. Transfus Med Hemother, 47, 152-9.
Moncharmont, P., Quittançon, E., Barday, G., & Benamara, A. (2019). Adverse transfusion reactions in patients with aplastic anaemia or myelodysplastic syndromes. Vox Sang,114(4), 349-54.
Moraes, E. S., Mello, M. S. C., Nogueira, F. A. M., Otero, U. B., & Carvalho, F. N. (2017). Análise de indivíduos com leucemia: limitações do sistema de vigilância de câncer. Ciênc saúde colet, 22(10), 3321-32.
Natukunda, B.,Schonewille, H., Vande Watering, L., & Brand, A. (2010) Prevalence and specificities of red blood cell alloantibodies in transfused Ugandans with different diseases. Vox Sang, 98(2), 167-71.
Noor, N. H. M., Arifin, N., Hassan, M. N., & Mustaffa, R. (2019). Red cell alloimmunization among haemato-oncologic patients in a teaching hospital in Malaysia. Sri Lanka Journal of Medicine, 28(1), 41-8.
Pahuja, S., Kushwaha, S., Sethi, N., Pujani, M., & Jain, M. (2012). Screening of blood donors for erythrocyte alloantibodies. Hematol, 17(5), 302-5.
Pessoni, L. L., Ferreira, M. A., Silva, J. C. R., & Alcântara, K. C. (2018).Red blood cell alloimmunization among hospitalized patients: transfusion reactions and low alloantibody identification rate. Hematol Transfus Cell Ther, 40(4), 326-31.
Pimpaldara, R. P., Patel, A. C., Patel, J., Patel, S., Pandya, A. N., & Wadhwani, S. (2015). A Study of Irregular Antibodies in 200 Multi-Transfused Patients. J Evol Med Dent Sci, 4(73), 12659-67.
Philip, J., Biswas, A. K., Hiregoudar, S., & Kushwaba, N. (2014).Red Blood Cell Alloimmunization in Multitransfused Patients in a Tertiary Care Center in Western India. Lab Med, 45(4), 324-30.
Reyhaneh, K., Ahmad, G., Gharib, K., Vida, V., Raheleh, K., & Mehdi, T. N. (2013). Frequency and specificity of RBC alloantibodies in patients due for surgery in Iran. Indian J Med Res,138(2), 252-6.
Rozovski, U., Ben-Tal, O., Kirgner, I., Mittelman, M., & Hareuveni, M. (2015). Increased Incidence of Red Blood Cell Alloantibodies in Myelodysplastic Syndrome. Isr Med Assoc J, 17(10), 624-7.
Singhal, D., Kutyna, M. M., Chhetri, R., Wee, L. Y. A., Hague, S., & Nath, L. (2017). Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome. Haematologica, 102(12), 2021-9.
Sood, R., Riana, V., & Rosamma, N. L. (2013). Detection of alloimmunization to ensure safer transfusion practice. Asian J Transfus Sci, 7(2), 135-9.
Storry, J. R., Clausen, F. B., Castilho, L., Chen, Q., Daniels, G., & Denomme, G. (2019). International Society of Blood Transfusion working party on red cell immunogenetics and blood group terminology: Report of the Dubai, Copenhagen and Toronto meetings. Vox Sang, 114(1), 95-102.
Tiwari, A. K., Pandey, P., Sharma, J., Shailja, K., Dixit, S., & Raina, V. (2014). Incidence of clinically significant antibodies in patients and healthy blood donors: a prospective cross-sectional study from a tertiary healthcare center in India. Transfusion and Apheresis Science, 50(2), 230-4.
Yamamoto, M.; & Figueiredo, V. L. P. (2005). Epidemiologia da leucemia linfocítica crônica e leucemia linfocítica crônica familiar. Rev Bras Hematol Hemoter, 27(4), 229-32.
Zalpuri, S., Evers, D., Zwaginga, J. J., Schonewille, H., Vooght, K. M. K., & Cessie, S. (2014). Immunosuppressants and alloimmunization against red blood cell transfusions. Transfusion, 54(8), 1981-7, 2014.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Danielle Stephane Ramos ; Mário Cézar de Oliveira; Sabrina Royer
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
